Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Safflor yellow A-containing pharmaceutical composition, its preparation method and usage

A technology of safflower yellow pigment and composition, applied in the directions of drug combination, pharmaceutical formulation, drug delivery, etc., can solve problems such as adverse reactions, stability defect of safflower injection, etc., to improve brain function and maintain nerve stress ability , Improve the effect of nerve cell metabolism

Inactive Publication Date: 2006-04-26
阿尔贝拉医药控股(通化)有限公司
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the stability of safflower injection is still defective, and there are reports of adverse reactions

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Example 1-Preparation of pharmaceutical composition

[0022] Safflower raw medicinal materials were added 30 times the volume (W / V) of 15% ethanol solvent, using a microwave with a frequency of 1100 MHz and a power of 12000 watts, and the extraction was carried out at 70°C for 5 times, each time for 50 minutes, and the extracts were combined. Add 30% acetone (V / V) and 0.3% crystallization aid caffeine (W / V, reagent to aid crystallization) into the extract, and let it stand for 36 hours. The crystals are safflower yellow pigment. Safflower yellow pigment is dissolved in water or 0.1-15% ethanol on macroporous resin, and eluted with 3 volumes of 5%, 15%, 30%, 45%, 60%, 75% and 90% ethanol. Collect, combine the 30% and 45% ethanol eluted fractions, and dry under reduced pressure to obtain safflower yellow pigment A.

[0023] According to the weight of acetoglutamine 100 times that of safflower yellow A, the ratio is obtained.

Embodiment 2

[0024] Example 2-Preparation of pharmaceutical composition

[0025] Safflower raw medicinal materials were added 50 times the volume of 30% ethanol solvent, and the microwave frequency was 1100 MHz and the power was 12000 watts. The extraction was carried out 5 times at 70°C for 50 minutes each time. The extracts were combined, and 30 was added to the extracts. % Acetone (V / V), 0.3% crystallization aid triethanolamine (W / V, reagent to aid crystallization), stand for 36 hours, and the crystals are safflower yellow pigment. The safflower yellow pigment is dissolved in water or methanol on a well-balanced dextran gel LH-20, eluted with water or methanol-water system (50:50), collected 1-2 column volumes of the components, combined, and reduced pressure Safflower yellow pigment A can be obtained after drying.

[0026] According to the weight of acetoglutamine 100 times that of safflower yellow A, the ratio is obtained.

Embodiment 3

[0027] Example 3-Preparation of pharmaceutical composition

[0028]Safflower raw medicinal materials were added with 100 times the volume (W / V) of 45% ethanol solvent, using a microwave with a frequency of 1100 MHz and a power of 12000 watts, and the extraction was carried out 5 times at 70°C for 50 minutes each time. The extracts were combined, Add 30% acetone (V / V) and 0.3% crystallization aid copoxine (W / V, reagent for assisting crystallization) into the extract and let stand for 36 hours. The crystals are safflower yellow pigment. The safflower yellow pigment is dissolved in water or methanol on the well-balanced Sephadex G-20, eluted with water, and the fractions of 1 to 1.5 column volumes are collected and combined, and dried under reduced pressure to obtain the safflower yellow pigment A.

[0029] According to the weight of acetoglutamine 100 times that of safflower yellow A, the ratio is obtained.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a pharmaceutical composition which is a compound preparation prepared from aceglutamide and Safflomin A. The pharmaceutical composition can be used for treating cerebrovascular diseases, liver stupor, memory obstacle, coronary disease and vascular diseases.

Description

Technical field [0001] The invention belongs to the technical field of medicine, and specifically relates to a pharmaceutical composition containing safflower yellow A, and specifically relates to a pharmaceutical composition made from acetoglutamine and safflower yellow A. The active ingredients of safflower are extracted with acetoglutamine. A novel pharmaceutical composition in available dosage form, its preparation method and its use in treating coma, paralysis, mental retardation, memory impairment and other diseases caused by occlusive cerebrovascular disease, hepatic coma, hemiplegia, neurosurgery, etc. Background technique [0002] Acetylglutamine is N 2 -Acetyl-L-glutamine (C 7 H 12 N 2 O 4 ) Is a white crystalline powder, which is often used clinically as a brain function improvement drug. The drug can pass through the blood-cerebrospinal fluid barrier and break down into glutamic acid and gamma-aminobutyric acid (GABA) after passing through the blood-cerebrospinal flui...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61K9/08A61K9/16A61K9/19A61K9/20A61K9/48A61K31/198A61P9/10A61P9/14
Inventor 张玉梅
Owner 阿尔贝拉医药控股(通化)有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com